Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Catalent, in its first quarter of fiscal year 2024, has displayed a robust start influenced by solid financial performance, despite the ongoing macroeconomic challenges.</li><li>The company reported a year-over-year revenue stabilization excluding the impact of COVID-19, with a noted 5% revenue increase in non-COVID sectors.</li><li>This performance is underpinned by notable demands in gene therapy services and strategic expansions in the GLP1 (glucagon-like peptide-1) domain, which collectively portend a continuation of mid to high-teens revenue growth for the fiscal year.</li></ul>

Catalent, in its first quarter of fiscal year 2024, has displayed a robust start influenced by solid financial performance, despite the ongoing macroeconomic challenges.The company reported a year-over-year revenue stabilization excluding the impact of COVID-19, with a noted 5% revenue increase in non-COVID sectors.This performance is underpinned by notable demands in gene therapy services and strategic expansions in the GLP1 (glucagon-like peptide-1) domain, which collectively portend a continuation of mid to high-teens revenue growth for the fiscal year.

Catalent Inc.: Leveraging Gene Therapy Expertise But Is It Enough? - Major Drivers

<ul><li>Catalent, a global leader in providing development, manufacturing, and delivery technologies for drugs and biologics, has exhibited both solid performance and areas of challenge in their preliminary financial results for the first quarter of fiscal year 2024.</li><li>The company has reaffirmed its full-year guidance, despite the persisting headwinds in various markets which the management team addressed through operational effectiveness and strategic reviews.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Catalent, a global leader in providing development, manufacturing, and delivery technologies for drugs and biologics, has exhibited both solid performance and areas of challenge in their preliminary financial results for the first quarter of fiscal year 2024.The company has reaffirmed its full-year guidance, despite the persisting headwinds in various markets which the management team addressed through operational effectiveness and strategic reviews.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Catalent Inc.: Gene Therapy Advancements Indicate A Bright Future Ahead? - Major Drivers

<ul><li>This is our first report on healthcare tech solutions provider, Catalent Inc.</li><li>The company's first quarter of fiscal year 2024 earnings call highlighted a solid start to the fiscal year despite turbulence in several markets.</li><li>The management noted improved focus on cash flow, citing benefits from better working capital management and increased analytical rigor around capital expenditure spending.</li></ul>

This is our first report on healthcare tech solutions provider, Catalent Inc.The company's first quarter of fiscal year 2024 earnings call highlighted a solid start to the fiscal year despite turbulence in several markets.The management noted improved focus on cash flow, citing benefits from better working capital management and increased analytical rigor around capital expenditure spending.

Catalent: Initiation of Coverage - How Their Ongoing Strategic Review Could Unleash Unprecedented Growth! - Major Drivers

Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>In this Original, we have provided an analysis of why we believe APAC healthcare sector is poised for stellar growth in long-term, mainly driven by its favorable demographics.</li>
<li>We have handpicked four APAC healthcare companies, with market cap of $5 billion+ and ADTV of $5 million+ and analyzed their long-term growth stories and fundamentals.</li>
<li>In additions, we have also provided a table for stocks of interest in APAC healthcare sector.</li>
</ul>


In this Original, we have provided an analysis of why we believe APAC healthcare sector is poised for stellar growth in long-term, mainly driven by its favorable demographics.
We have handpicked four APAC healthcare companies, with market cap of $5 billion+ and ADTV of $5 million+ and analyzed their long-term growth stories and fundamentals.
In additions, we have also provided a table for stocks of interest in APAC healthcare sector.


Smartkarma Originals: APAC Healthcare Series - Top Picks Are Poised for Multi-Year Growth

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>The S&amp;P 500 index tracks the 500 largest names listed in the US and it is one of the most highly-tracked indices in the world.</li>
<li>In this insight, we take a look at the upcoming constituent changes in the run up to the December 2024 index rebal event.</li>
<li>We expect two regular changes in December 2024. There are also several live spin-off and M&amp;A events which could trigger intra-review index changes in late-2024/early-2025.</li>
</ul>


The S&amp;P 500 index tracks the 500 largest names listed in the US and it is one of the most highly-tracked indices in the world.
In this insight, we take a look at the upcoming constituent changes in the run up to the December 2024 index rebal event.
We expect two regular changes in December 2024. There are also several live spin-off and M&amp;A events which could trigger intra-review index changes in late-2024/early-2025.


Quiddity Leaderboard S&P 500 Dec 24: APP, APO, and TPL May Be ADDs, Watch SP600 DELs

United States

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics and consumer health products. The Company's oral, injectable, and respiratory delivery technologies address the diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Catalent Inc (CTLT US)

Catalent Inc.: Leveraging Gene Therapy Expertise But Is It Enough? - Major Drivers

Catalent, in its first quarter of fiscal year 2024, has displayed a robust start influenced by solid financial performance, despite the ongoing...

Baptista Research

Catalent Inc.: Gene Therapy Advancements Indicate A Bright Future Ahead? - Major Drivers

Catalent, a global leader in providing development, manufacturing, and delivery technologies for drugs and biologics, has exhibited both solid...

Baptista Research

Catalent: Initiation of Coverage - How Their Ongoing Strategic Review Could Unleash Unprecedented Growth! - Major Drivers

This is our first report on healthcare tech solutions provider, Catalent Inc. The company's first quarter of fiscal year 2024 earnings call...

Baptista Research

Smartkarma Originals: APAC Healthcare Series - Top Picks Are Poised for Multi-Year Growth

APAC healthcare is among the world’s fastest growing markets, thereby gaining importance from investors. We have highlighted 4 APAC healthcare...

Tina Banerjee

Quiddity Leaderboard S&P 500 Dec 24: APP, APO, and TPL May Be ADDs, Watch SP600 DELs

The S&P500/400/600 Dec24 review will be announced in just over 10 days. There is an intra-review change in SP600 first, and perhaps a few more in...

Travis Lundy

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)